HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

VIR — Vir Biotechnology Inc.

VIR (Vir Biotechnology Inc.) stock: $13.13, $2.25B market cap, $454.6M cash, $1.79B EV, $2.30B fully diluted market cap. Lead program: Tobevibart (Viral Hepatitis), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

We are focused on developing therapies that enhance the immune system’s ability to overcome these evasion tactics, effectively powering the immune system to combat viruses and fight cancer. We believe our unified approach of leveraging our deep understanding of immunology to address seemingly disparate threats distinguishes us in the field.

Source: 10-K FY2025 via SEC EDGAR

Share price
$13.13
Market cap
$2,248.8M
Cash
$454.6M
Enterprise value
$1,794.2M

Balance sheet

Cash$454.6M
Debt$0.0M
Net cash$454.6M
Enterprise value$1,794.2M
Basic shares171.3M shares
Fully diluted shares174.9M shares
Fully diluted market cap$2,296.5M
Cash per share$2.65
Quarterly burn+$123.3M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common
169.2M
Pre-funded warrants
0.0M
Options
—
RSUs
5.7M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
174.9M

Cap table as of 2026-10-28.

Price history

Loading VIR daily closes…

Loading price history…

Next catalyst

Tobevibart · Dec 13, 2026 - Jan 24, 2027 in 5 wks · Phase 2 · Viral Hepatitis

Recently reported

Tobevibart Phase 3 Positive · 2026-11-09
viral hepatitis
Primary: Undetectable virus (HDV RNA target not detected) plus ALT normalization at Week 48 — 44% with elebsiran + tobevibart versus 0% in the delayed treatment group at Week 12 (p<0.0001)
· Key secondary endpoint: 79% achieved undetectable virus (HDV RNA TND) at Week 48 versus 0%
· Virologic response 100%
· ALT normalization 53% versus 5%
· ECLIPSE 1 enrolled 124 patients, randomized 2:1
· HDV RNA TND achieved in 85% of cirrhotic patients (n=46) and 73% of non-cirrhotic patients (n=37)
Safety: Well tolerated; one Grade 3 treatment-related adverse event (neutrophil count decrease, resolved in 15 days), no treatment interruptions or discontinuations; most common treatment-related adverse event was flu-like symptoms
Source release →
elebsiran + tobevibart Phase 3 Positive · 2026-11-08
viral hepatitis
Primary: Undetectable virus (HDV RNA target not detected) plus ALT normalization at Week 48 — 44% response rate versus 0% in the delayed treatment group at Week 12 (p<0.0001)
· Key secondary endpoint: 79% achieved undetectable virus at Week 48 versus 0%
· Virologic response 100%
· ALT normalization 53% versus 5%
· 124 patients enrolled, randomized 2:1
· HDV RNA TND achieved in 85% of cirrhotic patients (n=46) and 73% of non-cirrhotic patients (n=37)
· ECLIPSE 2 and ECLIPSE 3 data expected in the first quarter of 2027; FDA submission planned in mid-2027
Safety: Well tolerated; one Grade 3 treatment-related adverse event (neutrophil count decrease, which resolved in 15 days) and no treatment interruptions or discontinuations; most common treatment-related adverse event was flu-like symptoms
Source release →
elebsiran + tobevibart Phase 2 Positive · 2026-11-08
viral hepatitis
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego